Invivo performance of a drug-eluting contact lens to treat glaucoma for a month

Biomaterials

Volumn 35, Issue 1, 2014, Pages 432-439

  Ciolino, Joseph B ^a,b,c   Stefanescu, Cristina F ^a,b,c   Ross, Amy E ^a,b,c   Salvador Culla, Borja ^a,b,c   Cortez, Priscila ^b,c   Ford, Eden M ^b,c   Wymbs, Kate A ^b,c   Sprague, Sarah L ^b,c   Mascoop, Daniel R ^b,c   Rudina, Shireen S ^b,c   Trauger, Sunia A ^d   Cade, Fabiano ^a   Kohane, Daniel S ^b,c  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Contact lens; Drug delivery; Glaucoma; Latanoprost; Ocular release; Sustained release

Indexed keywords

ANIMAL STUDIES; CONTROLLED DRUG RELEASE; GLAUCOMA; LATANOPROST; OCULAR DRUG DELIVERY; OCULAR RELEASE; SUSTAINED RELEASE; ULTRA-VIOLET LIGHT;

ANIMAL CELL CULTURE; DRUG DELIVERY; DRUG PRODUCTS; OPHTHALMOLOGY; POLYMER FILMS;

CONTACT LENSES;

LATANOPROST; METHAFILCON; POLYGLACTIN; POLYMER; UNCLASSIFIED DRUG; PROSTAGLANDIN F;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; CONTACT LENS; CONTROLLED STUDY; DEVICE SAFETY; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG ELUTING CONTACT LENS; ENCAPSULATION; GLAUCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OPHTHALMIC DRUG DELIVERY DEVICE; POLYMERIZATION; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; ULTRAVIOLET RADIATION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG STABILITY; INTRAOCULAR PRESSURE; OCULAR RELEASE; RABBIT;

ANIMALIA;

CONTACT LENS; DRUG DELIVERY; GLAUCOMA; LATANOPROST; OCULAR RELEASE; SUSTAINED RELEASE;

ANIMALS; CONTACT LENSES; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GLAUCOMA; INTRAOCULAR PRESSURE; PROSTAGLANDINS F, SYNTHETIC; RABBITS;

EID: 84887017964     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.032     Document Type: Article

References (36)

1. Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G.P., et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004, 82(11):844-851.
2. Ghate D., Edelhauser H. Barriers to glaucoma drug delivery. JGlaucoma 2008, 17(2):147.
3. Nordstrom B.L., Friedman D.S., Mozaffari E., Quigley H.A., Walker A.M. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005, 140(4):598-606.
4. Sleath B., Blalock S., Covert D., Stone J.L., Skinner A.C., Muir K., et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology 2011, 118(12):2398-2402.
5. Bengani L.C., Hsu K.-H., Gause S., Chauhan A. Contact lenses as a platform forocular drug delivery. Expert Opin Drug Deliv 2013 Jul 22, [Epub ahead of print].
6. Ciolino J.B., Dohlman C.H., Kohane D.S. Contact lenses for drug delivery. Semin Ophthalmol 2009, 24(3):156-160.
7. Ciolino J.B., Hoare T.R., Iwata N.G., Behlau I., Dohlman C.H., Langer R., et al. Adrug-eluting contact lens. Invest Ophthalmol Vis Sci 2009, 50(7):3346-3352.
8. Ciolino J.B., Hudson S.P., Mobbs A.N., Hoare T.R., Iwata N.G., Fink G.R., et al. Aprototype antifungal contact lens. Invest Ophthalmol Vis Sci 2011, 52(9):6286-6291.
9. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21(23):2475-2490.
10. Berenson K.L., Kymes S.K., Hollander D.A., Fiscella R., Burk C., Patel V. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma. Am J Manag Care 2011, 17(9):e365-e374.
11. Stjernschantz J. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor lecture. Invest Ophthalmol Vis Sci 2001, 42(6):1134.
12. Mehta J., Patel V., Kshatri N., Vyas N. Aversatile LC method for the simultaneous quantification of latanoprost, timolol and benzalkonium chloride and related substances in the presence of their degradation products in ophthalmic solution. Anal Methods 2010, 2(11):1737-1744.
13. Convention USP Chemical tests/chapter (467) organic volatile impurities 2007, United States Pharmacopeia and National Formulary, Rockville, MD.
14. Gipson I.K., Spurr-Michaud S., Argüeso P., Tisdale A., Ng T.F., Russo C.L. Mucin gene expression in immortalized human corneal-limbal and conjunctival epithelial cell lines. Invest Ophthalmol Vis Sci 2003, 44(6):2496-2506.
15. Ophthalmic optics - contact lenses and contact lens care products - Determination of biocompatibility by ocular study with rabbit eyes 1998, ISO 9394, Geneva. 2nd ed.
16. Huang X., Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. JControl Release 2001, 73(2-3):121-136.
17. Riviere J.E. Comparative pharmacokinetics 2011, Wiley-Blackwell.
18. Morgan P.V., Proniuk S., Blanchard J., Noecker R.J. Effect of temperature and light on the stability of latanoprost and its clinical relevance. JGlaucoma 2001, 10(5):401-405.
19. Ochiai A., Danjo K. The stabilization mechanism of latanoprost. Int J Pharm 2011, 410(1-2):23-30.
20. Johnson T.V., Gupta P.K., Vudathala D.K., Blair I.A., Tanna A.P. Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use. JOcul Pharmacol Ther 2011, 27(1):51-59.
21. Jose M.V., Thomas V., Dean D.R., Nyairo E. Fabrication and characterization of aligned nanofibrous PLGA/collagen blends as bone tissue scaffolds. Polymer 2009, 50(15):3778-3785.
22. Ament J.D., Spurr-Michaud S.J., Dohlman C.H., Gipson I.K. The Boston Keratoprosthesis: comparing corneal epithelial cell compatibility with titanium and PMMA. Cornea 2009, 28(7):808-811.
23. Konynenbelt B.J., Mlnarik D.S., Ubels J.L. Effects of peroxide-based contact lens-disinfecting systems on human corneal epithelial cells invitro. Eye Contact Lens 2011, 37(5):286-297.
24. Sjöquist B., Basu S., Byding P., Bergh K., Stjernschantz J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos 1998, 26(8):745-754.
25. Sjöquist B., Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002, 47(Suppl.1):S6-S12.
26. Friström B., Nilsson S. Adouble masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily inopen angle glaucoma and ocular hypertension. Br J Ophthalmol 1997, 81(10):867.
27. Alm A., Villumsen J. PhXA34, a new potent ocular hypotensive drug: a study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991, 109(11):1564.
28. Daull P., Buggage R., Lambert G., Faure M.-O., Serle J., Wang R.-F., et al. Acomparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models. JOcul Pharmacol Ther 2012, 28(5):515-523.
29. Levy G. Effect of dosage form on drug absorption a frequent variable in clinical pharmacology. Arch Int Pharmacodyn Ther 1964, 152:59-68.
30. Levy G., Hollister L.E. Inter- and intrasubject variations in drug absorption kinetics. JPharm Sci 1964, 53:1446-1452.
31. Occupational health guidelines for ethyl acetate. Available from:. http://www.cdc.gov/niosh/docs/81-123/pdfs/0260.pdf.
32. Green K., Edelhauser H.F., Hackett R.B. Advances in ocular toxicology 1997, Springer.
33. Bozkir G., Bozkir M., Dogan H., Aycan K., Güler B. Measurements of axial length and radius of corneal curvature in the rabbit eye. Acta Med Okayama 1997, 51(1):9-11.
34. Wichterle O, Lim D. Cross-linked hydrophilic polymers and articles made there from. US Patent No. 3,220,960. 1965.
35. Tsai J.C. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol 2006, 17(2):190-195.
36. Kass M.A., Hodapp E., Gordon M., Kolker A.E., Goldberg I. Patient administration of eyedrops: observation. Part II. Ann Ophthalmol 1982, 14(9):889-893.